NVCT Share Price Performance
US$6.01
-0.07 (-1.07%)
Price US$6.01
Share PriceUS$6.01
Nuvectis Pharma, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
NVCT Community Narratives
There are no narratives available yet.
Recent NVCT News & Updates
Nuvectis Pharma, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.87
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Nuvectis Pharma, Inc. Competitors
Snowflake Analysis
About NVCT
- Founded
- 2020
- Employees
- 13
- CEO
- WebsiteView website
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.2%
- 3 Months: 8.5%
- 1 Year: 17.7%
- Year to Date: 14.8%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. The market is up 18% over the last 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›